Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that members of the management team, including Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder, and Liz Bhatt, MS, MBA, Chief Operating Officer, will participate in the following investor and industry conferences:

Evercore ISI 2024 Emerging Private Biotech Conference

Presentation: Wednesday, February 28, 2024, at 2:50 p.m. ET.

Location: Virtual.

TD Cowen 44^th Annual Health Care Conference

Participation: Monday, March 4, 2024.

Location: Boston, MA.

Fierce Biotech 2024 Business Development and Licensing Summit

Panel: “Dynamics and Structures for Negotiating and Evaluating Platform Deals” on Monday, March 11, 2024, at 1:15 p.m. PT.

Location: San Francisco, CA.

Leerink Partners 2024 Global Biopharma Conference

Participation: Wednesday, March 13, 2024.

Location: Miami, FL.

About Septerna

Septerna, Inc. is a biotechnology company focused on advancing novel, oral small molecule medicines targeting the entire class of G protein-coupled receptors (GPCRs). The company’s Native Complex Platform™ recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment to rapidly apply new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. Septerna was launched in 2022 by scientific founders who have made groundbreaking GPCR discoveries. For more information, please visit www.septerna.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222273396/en/